PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Clinical trial NCT03955354 · UNKNOWN
Trial details
- NCT number
- NCT03955354
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-05
- Primary completion
- 2020-04-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.